Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Tissue Engineering Laboratory and Berlin-Brandenburg Center for Regenerative Therapies, Charitéplatz 1, 10117, Berlin, Germany.
Julius Wolff Institute and Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Föhrer Straße 15, 13353, Berlin, Germany.
J Orthop Res. 2019 Aug;37(8):1723-1729. doi: 10.1002/jor.24312. Epub 2019 Apr 29.
There is evidence that the application of mesenchymal stromal cells (MSCs) counteracts osteoarthritis (OA) progression. However, the prospect of extracting and expanding these cells might be limited. The aim of this study was to investigate whether hyaluronic acid (HA) supplemented with MSC-recruiting chemokine C-C motif ligand 25 (CCL25) can influence the natural course of spontaneous OA in the guinea pig. CCL25 concentration in synovial fluid (SF) was quantified with enzyme-linked immunosorbent assay. Boyden chamber cell migration assay was used to test CCL25-mediated migration of guinea pig MSC. Forty-nine 11-month-old male guinea pigs were divided into seven groups. The main treatments consisted of five intra-articular injections of HA in pure form and in combination with three doses of CCL25 (63, 693, and 6,993 pg) given at a weekly interval. The severity of cartilage damage was assessed by using a modified Mankin score. The measured average physiological concentration of CCL25 in SF of animals is 85 ± 39 pg/ml. MSC showed a 3.2-fold increase in cell migration at 1,000 nM CCL25 in vitro demonstrating the biological migratory activity of CCL25 on these cells. In vivo, treatment with HA alone did not reduce OA progression. Similarly, OA scores were not found significantly reduced after treatment with 63 pg CCL25 + HA. However, when compared to pure HA, treatment with 693 pg CCL25 + HA and 6,993 pg CCL25 + HA significantly reduced the OA score from 10.1 to 7.4 (-28%) and 8.4 (-20%), respectively. These data suggest that intra-articular injections of HA supplemented with CCL25 attenuates OA. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:1723-1729, 2019.
有证据表明,间充质基质细胞(MSCs)的应用可以对抗骨关节炎(OA)的进展。然而,提取和扩增这些细胞的前景可能有限。本研究旨在探讨透明质酸(HA)联合 MSC 募集趋化因子 C-C 基序配体 25(CCL25)是否能影响豚鼠自发性 OA 的自然病程。通过酶联免疫吸附试验定量检测滑液(SF)中的 CCL25 浓度。使用 Boyden 室细胞迁移试验测试豚鼠 MSC 介导的 CCL25 迁移。将 49 只 11 月龄雄性豚鼠分为 7 组。主要处理包括五次关节内注射纯 HA 和每周一次注射三种剂量的 CCL25(63、693 和 6993pg)。通过改良的 Mankin 评分评估软骨损伤的严重程度。动物 SF 中 CCL25 的测量平均生理浓度为 85±39pg/ml。体外 MSC 在 1000nM CCL25 作用下迁移率增加 3.2 倍,证明 CCL25 对这些细胞具有生物迁移活性。体内,单独使用 HA 治疗不能减缓 OA 的进展。同样,用 63pg CCL25+HA 治疗也未发现 OA 评分显著降低。然而,与纯 HA 相比,用 693pg CCL25+HA 和 6993pg CCL25+HA 治疗分别使 OA 评分从 10.1 降至 7.4(-28%)和 8.4(-20%),表明关节内注射 HA 联合 CCL25 可减轻 OA。©2019 骨科研究协会。 Wiley Periodicals, Inc. 出版 J 骨科研究 37:1723-1729, 2019。